Brought to you by 
Schering-Plough acquires NeoGenesis
19 May 2005
Executive Summary
Schering-Plough has agreed to acquire privately held NeoGenesis (developing small-molecule drugs) in order to strengthen its drug discovery technology and IP portfolio. It paid $18mm up front and provides earn-outs for certain development achievements.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough acquires NeoGenesis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice